Share this article
Share this article
TORONTO, May 3, 2021 /PRNewswire/ -
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that the Company has filed a novel cancer adjuvant patent and is proceeding with pre-clinical trials with third-party cancer Contract Research Organizations (CROs) in triple-negative breast cancer, metastatic melanoma, and lung carcinoma.
Summary
MVMD files cancer patent for direct intratumoral injection, intravenously, infusions or instillations as adjuvants for broad chemotherapeutic to immunotherapeutic cancer regimens.
The Company is proceeding with three separate pre-clinical trials with specialized third-party cancer CROs: (1) triple-negative breast cancer; (2) metastatic melanoma; and (3) Lewis Lung Carcinoma as a proxy for non-small cell lung carcinoma.
Mountain Valley MD Commencing Trials in Bangladesh, Striking Pharmaceutical Production Agreements
News provided by
Share this article
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it is commencing husbandry animal trials under the supervision of The People s Republic of Bangladesh s Ministry of Fisheries & Livestock for the Company s injectable solubilized Ivermectin technology, Ivectosol™ 1%. We are very excited to be welcoming Mountain Valley MD to The People s Republic of Bangladesh and are proud that they have selected our country for important research projects and as a key production hub for its solubilized Ivectosol™ 1% product, stated Bangladesh s Foreign Minister H.E. Dr. A. K. Abdul Momen, M.P.
Mountain Valley MD Files for Acceleration of Patent Examination for Solubilized Ivermectin
News provided by
Share this article
Mountain Valley MD Holdings Inc. (the
Company or
MVMD ) (CSE: MVMD) (FRA: 20MP) is pleased to announce that it has filed for an accelerated review of its macrocyclic lactone solubilization patent with the United States Patent and Trademark Office ( USPTO ).
To support the accelerated patent examination request, the Company has provided the USPTO with new formulation analyses of different diluted concentrations of its Quicksol™ Ivermectin in solution, data that the company had fast-tracked for completion and validation by a third-party CRO.
The Company previously confirmed its ability to make the anti-parasitic drug Ivermectin highly water-soluble without the use of organic solvents, improving its water solubility by nearly 5,000 times and that it had completed its initial safety and improved efficacy in pre-clinical validation with a leading t